JP2024518497A5 - - Google Patents
Info
- Publication number
- JP2024518497A5 JP2024518497A5 JP2023569789A JP2023569789A JP2024518497A5 JP 2024518497 A5 JP2024518497 A5 JP 2024518497A5 JP 2023569789 A JP2023569789 A JP 2023569789A JP 2023569789 A JP2023569789 A JP 2023569789A JP 2024518497 A5 JP2024518497 A5 JP 2024518497A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- inhibitor
- composition according
- solvate
- menin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2021093036 | 2021-05-11 | ||
| CNPCT/CN2021/093036 | 2021-05-11 | ||
| CN2021100523 | 2021-06-17 | ||
| CNPCT/CN2021/100523 | 2021-06-17 | ||
| CN2022086004 | 2022-04-11 | ||
| CNPCT/CN2022/086004 | 2022-04-11 | ||
| PCT/CN2022/091679 WO2022237720A1 (en) | 2021-05-11 | 2022-05-09 | Combination therapies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024518497A JP2024518497A (ja) | 2024-05-01 |
| JP2024518497A5 true JP2024518497A5 (https=) | 2025-05-19 |
Family
ID=81753154
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023569789A Pending JP2024518497A (ja) | 2021-05-11 | 2022-05-09 | 併用療法 |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP4337216A1 (https=) |
| JP (1) | JP2024518497A (https=) |
| KR (1) | KR20240006631A (https=) |
| CN (2) | CN117460513A (https=) |
| AU (1) | AU2022274071A1 (https=) |
| CA (1) | CA3215313A1 (https=) |
| CL (2) | CL2023003239A1 (https=) |
| CO (1) | CO2023014322A2 (https=) |
| DO (1) | DOP2023000246A (https=) |
| IL (1) | IL308335A (https=) |
| MX (1) | MX2023013410A (https=) |
| PE (1) | PE20240593A1 (https=) |
| PH (1) | PH12023552974A1 (https=) |
| TW (1) | TW202308643A (https=) |
| UY (1) | UY39761A (https=) |
| WO (1) | WO2022237720A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202525813A (zh) | 2019-12-19 | 2025-07-01 | 比利時商健生藥品公司 | 經取代之直鏈螺環接衍生物 |
| EP4626426A1 (en) * | 2022-11-30 | 2025-10-08 | JANSSEN Pharmaceutica NV | Combinations comprising a menin-mll inhibitor and at least one other therapeutic agent |
| WO2024114666A1 (en) * | 2022-11-30 | 2024-06-06 | Janssen Pharmaceutica Nv | Combinations comprising a menin-mll inhibitor and a bcl-2 inhibitor |
| EP4698182A1 (en) * | 2023-04-17 | 2026-02-25 | Janssen Pharmaceutica NV | Combination of a menin-ll1 inhibitor, a dna intercalating agent and a pyrimidine analogue to treat a hematopoietic disorder |
| WO2025082444A2 (en) * | 2023-10-20 | 2025-04-24 | Janssen Pharmaceutica Nv | (r) -n-ethyl-5-fluoro-n-isopropyl-2- ( (5- (2- (6- ( (2-methoxyethyl) (methyl) amino) -2-methylhexan-3-yl) -2, 6-diazaspiro [3.4] octan-6-yl) -1, 2, 4-triazin-6-yl) oxy) benzamide, formulations and dosage regimens thereof, for use in treating cancer |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TN2017000080A1 (en) | 2014-12-18 | 2018-07-04 | Takeda Pharmaceuticals Co | Solid state forms of fused heteroaromatic pyrrolidinones |
| AU2016378579A1 (en) * | 2015-12-22 | 2018-06-14 | Vitae Pharmaceuticals, Inc. | Inhibitors of the menin-MLL interaction |
| WO2017214367A1 (en) * | 2016-06-10 | 2017-12-14 | Vitae Pharmaceuticals, Inc. | Inhibitors of the menin-mll interaction |
| TW202104207A (zh) | 2019-04-17 | 2021-02-01 | 美商健生生物科技公司 | 二氫乳清酸脫氫酶抑制劑 |
| TW202525813A (zh) | 2019-12-19 | 2025-07-01 | 比利時商健生藥品公司 | 經取代之直鏈螺環接衍生物 |
-
2022
- 2022-05-09 MX MX2023013410A patent/MX2023013410A/es unknown
- 2022-05-09 KR KR1020237042402A patent/KR20240006631A/ko active Pending
- 2022-05-09 PH PH1/2023/552974A patent/PH12023552974A1/en unknown
- 2022-05-09 PE PE2023003030A patent/PE20240593A1/es unknown
- 2022-05-09 EP EP22725158.4A patent/EP4337216A1/en active Pending
- 2022-05-09 CA CA3215313A patent/CA3215313A1/en active Pending
- 2022-05-09 WO PCT/CN2022/091679 patent/WO2022237720A1/en not_active Ceased
- 2022-05-09 JP JP2023569789A patent/JP2024518497A/ja active Pending
- 2022-05-09 CN CN202280034525.XA patent/CN117460513A/zh active Pending
- 2022-05-09 CN CN202410897512.6A patent/CN118845787A/zh active Pending
- 2022-05-09 IL IL308335A patent/IL308335A/en unknown
- 2022-05-09 AU AU2022274071A patent/AU2022274071A1/en active Pending
- 2022-05-10 UY UY0001039761A patent/UY39761A/es unknown
- 2022-05-10 TW TW111117441A patent/TW202308643A/zh unknown
-
2023
- 2023-10-25 CO CONC2023/0014322A patent/CO2023014322A2/es unknown
- 2023-10-31 CL CL2023003239A patent/CL2023003239A1/es unknown
- 2023-11-08 DO DO2023000246A patent/DOP2023000246A/es unknown
-
2024
- 2024-09-23 CL CL2024002832A patent/CL2024002832A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024518497A5 (https=) | ||
| JP2024519322A5 (https=) | ||
| JP5046922B2 (ja) | 少なくとも一つのピロロベンゾジアゼピン誘導体とフルダラビンとを含有する治療用組成物 | |
| US12350265B2 (en) | Pharmaceutical composition for treating acute myeloid leukemia, containing FLT3 inhibitor and chemotherapeutic agents | |
| US20030060450A1 (en) | Dosing regimen | |
| JP2002519389A (ja) | インビボ放射線増感特性をもつファルネシルタンパク質トランスフェラーゼ阻害剤 | |
| JP2006501176A5 (https=) | ||
| CN118903436A (zh) | 治疗肥大细胞增多症的组合疗法 | |
| JP2012520313A5 (https=) | ||
| KR20250065935A (ko) | 암을 치료하기 위한 테트라사이클릭 퀴놀론 유사체의 병행 요법 | |
| KR20160067118A (ko) | (ｓ)-3-(4-((4-(모르폴리노메틸)벤질)옥시)-1-옥소이소인돌린-2-일)피페리딘-2,6-디온의 제제 | |
| JP2003525238A (ja) | 抗腫瘍性ポドフィロトキシン誘導体とのファルネシルタンパク質トランスフェラーゼ阻害剤組み合わせ剤 | |
| JP2003525244A (ja) | 抗腫瘍性アルキル化剤とのファルネシルタンパク質トランスフェラーゼ阻害剤組み合わせ剤 | |
| Yasui et al. | SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma | |
| JP2003525235A (ja) | 抗腫瘍ヌクレオシド誘導体とのファルネシルタンパク質トランスフェラーゼ阻害剤の組み合わせ剤 | |
| JP2003525245A (ja) | ファルネシルタンパク質トランスフェラーゼ阻害剤組み合わせ剤 | |
| CN1373666A (zh) | 对氧化毒性物质,特别是对心脏毒性物质具有保护作用的药物 | |
| JP2024518434A5 (https=) | ||
| JP2003525237A (ja) | 抗腫瘍性アントラサイクリン誘導体とのファルネシルタンパク質トランスフェラーゼ阻害剤組み合わせ剤 | |
| CN107922321A (zh) | 脲基氮芥(bo‑1055)在癌症治疗上的用途 | |
| US6822001B2 (en) | Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents | |
| TW201235039A (en) | Composition, kit and use for immune enhancement | |
| KR20240144146A (ko) | Malt1 저해약을 유효 성분으로서 포함하는 암 치료제 | |
| CN120659608A (zh) | 用于治疗癌症的tead抑制剂和kras g12d抑制剂组合 | |
| EP2107906A2 (fr) | Nouvelle utilisation therapeutique pour le traitement des leucemies |